Clinical Trial Details

EORTC-62072-STBSG

Back to Clinical Trials Database

A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.

Study documentation Publications

Trial Status All trial activities ended
Dates Date of activation: 01-Oct-2008
Date Step1 close: 08-Mar-2010
Data management at EORTC Yes
Design Phase 3
Randomized blind
Targeted Sample size All Groups: 255
Treatment Drug
Pazopanib
Study Staff Saskia Litiere (Statistician) saskia.litiere (at) eortc.org, EORTC Headquarters, Brussels
Sandrine Marreaud (Clinical Research Physician) sandrine.marreaud (at) eortc.org, EORTC Headquarters, Brussels
Edwin Nys (Data Manager) edwin.nys (at) eortc.org, EORTC Headquarters, Brussels
Axelle Nzokirantevye (Data Manager) axelle.nzokirantevye (at) eortc.org, EORTC Headquarters, Brussels
Type of cancer Soft Tissue and Bone Sarcoma
Participating groups EORTC Soft Tissue and Bone Sarcoma Group
Recruiting centers Advocate Illinois Masonic Creticos Cancer Center (Chicago, United States of America)
Asan Medical Center (Seoul, Korea (Republic of))
Ashford Cancer Centre (Kurralta Park, Australia)
Azienda Ospedaliera S. Maria (Terni, Italy)
Box Hill Hospital (Box Hill, Australia)
C.H.U. Sart-Tilman (Liege, Belgium)
Case Western Reserve University School of Medicine (Cleveland, United States of America)
Cedars-Sinai Medical Center (Los Angeles, United States of America)
Centre Leon Berard (Lyon, France)
Centre Oscar Lambret (Lille, France)
Chiba Cancer Center (Chiba, Japan)
Cliniques Universitaires Saint-Luc (Brussels, Belgium)
Dana-Farber Cancer Institute & Harvard Medical School (Boston, United States of America)
Erasmus MC (Rotterdam, Netherlands)
Fondazione IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Fondazione del Piemonte per l' Oncologia - Istituto di Candiolo-IRCCS (Candiolo (Torino), Italy)
Fundacion Instituto Valenciano De Oncologia (Valencia, Spain)
Gustave Roussy (Villejuif, France)
Helios Klinikum Bad Saarow (Bad Saarow-Pieskow, Germany)
Herlev Hospital - University Copenhagen (Herlev, Denmark)
Hospital Universitari Son Espases (Palma De Mallorca, Spain)
Hospital Universitario 12 De Octubre (Madrid, Spain)
Hospital Universitario San Carlos (Madrid, Spain)
Hôpital de La Timone (APHM) (Marseille, France)
Institut Curie- Hopital de Paris (Paris, France)
Institut Jules Bordet-Hopital Universitaire ULB (Brussels, Belgium)
Institut de Cancerologie de Lorraine (Vandoeuvre-Les-Nancy, France)
Institut de Cancerologie de la Loire Lucien Neuwirth (Saint Priest en Jarez, France)
Istituto Clinico Humanitas (Rozzano, Milano, Italy)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (Napoli, Italy)
Klinikum Der J.W. Goethe Universitaet (Frankfurt Am Main, Germany)
Leeds Teaching Hospitals NHS Trust - St. James's University Hospital (Leeds, United Kingdom)
Leiden University Medical Centre (Leiden, Netherlands)
Linkoping University Hospital (Linkoping, Sweden)
Medizinische Hochschule Hannover (Hannover, Germany)
Mie University Hospital (Mie, Japan)
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital (Glasgow, United Kingdom)
National Cancer Center (Gyeonggi-do, Korea (Republic of))
National Cancer Center Hospital (Tokyo, Japan)
National Hospital Organization Hokkaido Cancer Center (Hokkaido, Japan)
National Hospital Organization Osaka (Osaka, Japan)
National Kyushu Cancer Center (Fukuoka-City Fukuoka, Japan)
Nottingham University Hospitals NHS Trust - City Hospital (Nottingham, United Kingdom)
Okayama University Hospital (Okayama, Japan)
Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka, Japan)
Ospedale Gradenigo (Torino, Italy)
Ospedale Niguarda Ca Granda (Milano, Italy)
Pennsylvania Oncology Hematology Associates (Philadelphia, United States of America)
Prince Of Wales Hospital (Randwick - Sydney, Australia)
Radboud University Medical Center Nijmegen (Nijmegen, Netherlands)
Regina Elena National Cancer Center (Roma, Italy)
Royal Hobart Hospital (Hobart, Australia)
Royal Marsden Hospital - Chelsea, London (London, United Kingdom)
Sahlgrenska Universitetssjukhuset (Goteborg, Sweden)
Samsung Medical Center (Seoul, Korea (Republic of))
Sarcoma Oncology Center (Santa Monica, United States of America)
Seoul National University Hospital (Seoul, Korea (Republic of))
Severance Hospital, Yonsei University Health System ( YUCM) (Seoul, Korea (Republic of))
Sir Charles Gairdner Hospital (Nedlands, Australia)
Skane University Hospital (Lund, Sweden)
The Christie NHS Foundation Trust (Manchester, United Kingdom)
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (Amsterdam, Netherlands)
U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium)
Umea Universitet (Umea, Sweden)
UniversitaetsMedizin Mannheim (Mannheim, Germany)
Universitaetsklinikum - Essen (Essen, Germany)
Universitaetsklinikum Carl Gustav Carus (Dresden, Germany)
Universitaetsklinikum Heidelberg - Hospital for Internal Medicine (Heidelberg, Germany)
Universitaetsklinikum Koeln (Koeln, Germany)
University Medical Center Groningen (Groningen, Netherlands)
University of Alabama at Birmingham (Birmingham, United States of America)
University of Minnesota (Minneapolis, United States of America)
Uppsala University Hospital - Akademiska Sjukhuset (Uppsala, Sweden)
Youngnam University Hospital (Deagu, Korea (Republic of))
Centers to be activated Biocancer (Belo Horizonte, Brazil)
Centro de Pesquisas Clinicas em Oncologia (Porto Alegre, Brazil)
Hospital Erasto Gaertner (Curitiba, Brazil)
Instituto Nacional do Cancer INCA (Rio de Janeiro, Brazil)
Instituto de Oncologia do Parana (Curitiba, Brazil)
Newcastle Hospitals NHS Trust - Campus for Ageing and Vitality (Newcastle-Upon-Tyne, United Kingdom)
Ospedale Regionale "Ca' Foncello" (Treviso, Italy)
Universitair Ziekenhuis Gent (Gent, Belgium)
University College Hospital (London, United Kingdom)
Protocol summary http://clinicaltrials.gov/ct/show/NCT00794521
NCT number NCT00794521
EudraCT 2008-001307-33